TY  - JOUR
AU  - Montejo, Angel L
AU  - Arango, Celso
AU  - Bernardo, Miquel
AU  - Carrasco, Jose L
AU  - Crespo-Facorro, Benidicto
AU  - Cruz, Juan J
AU  - Del Pino-Montes, Javier
AU  - Garcia-Escudero, Miguel A
AU  - Garcia-Rizo, Clemente
AU  - Gonzalez-Pinto, Ana
AU  - Hernandez, Ana I
AU  - Martin-Carrasco, Manuel
AU  - Mayoral-Cleries, Fermin
AU  - Mayoral-van Son, Jaqueline
AU  - Mories, M Teresa
AU  - Pachiarotti, Isabella
AU  - Perez, Jesus
AU  - Ros, Salvador
AU  - Vieta, Eduard
PY  - 2017
DO  - 10.1016/j.yfrne.2017.02.003
UR  - http://hdl.handle.net/10668/10902
T2  - Frontiers in neuroendocrinology
AB  - Hyperprolactinemia is an underappreciated/unknown adverse effects of antipsychotics. The consequences of hyperprolactinemia compromise therapeutic adherence and can be serious. We present the consensus recommendations made by a group of experts...
LA  - en
PB  - Elsevier Inc.
KW  - Antipsychotic
KW  - Consensus
KW  - Hyperprolactinemia
KW  - Neuroleptic
KW  - Physical health
KW  - Antipsychotic Agents
KW  - Aripiprazole
KW  - Consensus
KW  - Humans
KW  - Hyperprolactinemia
KW  - Iatrogenic Disease
KW  - Mental Disorders
TI  - Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics.
TY  - research article
VL  - 45
ER  -